Get the Stockscreener App
4.74
3.85%
-0.19
After Hours:
4.74
Coya Therapeutics Inc stock is traded at $4.74, with a volume of 79,486.
It is down -3.85% in the last 24 hours and up +7.24% over the past month.
Coya Therapeutics Inc is a clinical-stage biotechnology company focused on developing proprietary medicinal products to modulate the function of regulatory T cells. It is developing its multi-modality Treg therapies for neurodegenerative, autoimmune, and metabolic diseases.
See More
Previous Close:
$4.93
Open:
$4.91
24h Volume:
79,486
Relative Volume:
0.37
Market Cap:
$99.18M
Revenue:
-
Net Income/Loss:
$-14.88M
P/E Ratio:
-4.8367
EPS:
-0.98
Net Cash Flow:
$-10.29M
1W Performance:
-4.82%
1M Performance:
+7.24%
6M Performance:
-24.40%
1Y Performance:
-27.30%
1-Day Range:
$4.68
$5.03
1-Week Range:
$4.59
$5.04
52-Week Range:
$3.9401
$7.75
Coya Therapeutics Inc Stock (COYA) Company Profile
Name
Coya Therapeutics Inc
Sector
Industry
Phone
650.739.3939
Address
12645 MEMORIAL DR., SUITE F1 #305, HOUSTON
Compare COYA vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
COYA
Coya Therapeutics Inc
|
4.74 | 103.16M | 0 | -14.88M | -10.29M | -0.98 |
|
VRTX
Vertex Pharmaceuticals Inc
|
460.82 | 121.40B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
764.93 | 83.25B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
728.11 | 46.39B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.51 | 43.41B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
292.94 | 33.09B | 5.36B | 287.73M | 924.18M | 2.5229 |
Coya Therapeutics Inc Stock (COYA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-09-25 | Initiated | Lake Street | Buy |
| Dec-04-24 | Initiated | D. Boral Capital | Buy |
Coya Therapeutics Inc Stock (COYA) Latest News
Aug Mood: Is Coya Therapeutics Inc benefiting from innovation trendsEarnings Overview Report & AI Driven Stock Reports - baoquankhu1.vn
COYA Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
New Highs: Is Coya Therapeutics Inc impacted by rising rates - baoquankhu1.vn
Trading the Move, Not the Narrative: (COYA) Edition - Stock Traders Daily
Coya Therapeutics, Inc. (NASDAQ:COYA) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Should I buy Coya Therapeutics Inc. stock nowGDP Growth & Real-Time Sentiment Analysis - mfd.ru
Coya Therapeutics, Inc. (COYA) Upgraded to Buy: What Does It Mean for the Stock? - Yahoo Finance
What’s the RSI of Coya Therapeutics Inc. stockJuly 2025 Levels & Fast Entry and Exit Trade Plans - mfd.ru
Coya Therapeutics’ (COYA) “Buy” Rating Reaffirmed at D. Boral Capital - Defense World
Coya Therapeutics (NASDAQ:COYA) Earns Buy Rating from D. Boral Capital - MarketBeat
Coya Therapeutics (COYA) Receives Buy Rating from Jason Kolbert - GuruFocus
Coya Therapeutics Details ALS Combo Immunotherapy Plan, Highlights Early Biomarker Signals in Webinar - MarketBeat
COYA Should I Buy - Intellectia AI
Exosomes Pipeline 2025: FDA Updates, Therapy Innovations, and Clinical Trial Landscape Analysis by DelveInsight | Innovex Therapeutics, Coya Therapeutics, EV Therapeutics, Endosome Therapy StemXO - Barchart.com
Published on: 2026-02-11 23:08:14 - baoquankhu1.vn
Coya Therapeutics to Host Webinar with Leading Medical Experts on Amyotrophic Lateral Sclerosis (ALS) Drug Development, Patient Landscape, and Ongoing Clinical Trial - BioSpace
Houston biotech co. raises $11M to advance ALS drug development - InnovationMap
New funding backs commercial readiness efforts for ALS therapy - ALS News Today
Price-Driven Insight from (COYA) for Rule-Based Strategy - Stock Traders Daily
HC Wainwright Predicts Higher Earnings for Coya Therapeutics - Defense World
HC Wainwright Analysts Raise Earnings Estimates for COYA - MarketBeat
Coya Therapeutics (NASDAQ:COYA) Receives “Buy” Rating from HC Wainwright - Defense World
Coya Therapeutics Announces $11.1 Million Private Placement - marketscreener.com
Coya Therapeutics (NASDAQ:COYA) Given "Buy" Rating at HC Wainwright - MarketBeat
H.C. Wainwright reiterates Buy rating on Coya Therapeutics stock with $18 target - Investing.com Canada
Coya Therapeutics, Inc. (NASDAQ:COYA) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
Take Profit: Is Coya Therapeutics Inc impacted by rising ratesWeekly Risk Summary & AI Powered Buy/Sell Recommendations - baoquankhu1.vn
Aug Outlook: Is Coya Therapeutics Inc impacted by rising ratesQuarterly Performance Summary & Reliable Entry Point Trade Alerts - baoquankhu1.vn
Aug Drivers: Will ACXP outperform its industry peersMarket Movement Recap & High Return Trade Guides - baoquankhu1.vn
Market Fear: Does Coya Therapeutics Inc have strong fundamentals2025 Top Decliners & Low Risk Entry Point Guides - baoquankhu1.vn
Coya Therapeutics to sell 2.522M shares at $4.40 in private placement - Yahoo Finance
Coya Therapeutics secures $11.1 million in private placement By Investing.com - Investing.com Australia
Coya Therapeutics secures $11.1 million in private placement - Investing.com India
Coya Therapeutics Sets $11.1 Million Private Placement Led by Dr. Reddy’s And Greenlight Capital - Pulse 2.0
Coya Therapeutics raises $11.1M in private placement led by Dr. Reddy's - MSN
Dr. Reddy's (RDY) Invests in Coya Therapeutics' Private Placemen - GuruFocus
Coya Therapeutics Announces Strategic Private Placement Financing - TipRanks
Coya Therapeutics Signs Securities Purchase Agreement With Dr. Reddy's Labs - TradingView
Coya Therapeutics, Inc. announced that it expects to receive $11.099999 million in funding - marketscreener.com
(COYA) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
Coya Therapeutics (COYA): Analyst Maintains 'Buy' Rating with St - GuruFocus
D. Boral Capital Reiterates Buy Rating for Coya Therapeutics (NASDAQ:COYA) - MarketBeat
Coya Therapeutics advances ALS and FTD clinical trials in 2026 By Investing.com - Investing.com South Africa
Coya Therapeutics Inc Stock (COYA) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.69%
0.68%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):